Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Aly‐Khan A. Lalani(Juravinski Cancer Centre), Toni K. Choueiri(Harvard University), Dylan J. Martini(Dana-Farber Cancer Institute), Xiao X. Wei(Dana-Farber Cancer Institute), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Lauren C. Harshman(Dana-Farber Cancer Institute), Rana R. McKay(University of California San Diego), Bradley A. McGregor(Harvard University), Wanling Xie(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Ronit Simantov(Pfizer (United States)), Dominick Bossé(Dana-Farber Cancer Institute), Xun Lin(Pfizer (United States)), Marina D. Kaymakcalan(Dana-Farber Cancer Institute)
Cited by 96
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k